Physician profile
Gunjan Raina
NPI 1437325206
$3,431.69
in general payments reported to CMS, 2019-2025
16 companies · $237 in 2025
The $237 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $548 · 2020: $390 · 2021: $635 · 2022: $1,014 · 2023: $482 · 2024: $125 · 2025: $237.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $844.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $844.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,633.68 | 2019-2023 | Wegovy, Ozempic, Rybelsus |
| Takeda Pharmaceuticals U.S.A., INC. | $428.24 | 2019-2025 | Trintellix |
| Amgen INC. | $304.32 | 2019-2022 | |
| Bausch Health US, LLC | $250.76 | 2021-2025 | Aplenzin, Wellbutrin |
| Abbvie INC. | $222.91 | 2021-2025 | |
| Lilly USA, LLC | $192.90 | 2022-2025 | Mounjaro, Zepbound, Jardiance |
| Novartis Pharmaceuticals Corporation | $117.00 | 2022-2025 | |
| Pfizer INC. | $71.84 | 2019-2023 | |
| Glaxosmithkline, LLC. | $71.22 | 2021-2023 | Trelegy Ellipta |
| Optinose US, INC. | $28.14 | 2019 | |
| Vivus LLC | $20.68 | 2022 | |
| Axsome Therapeutics, INC. | $19.07 | 2023 | Auvelity |
| Lundbeck LLC | $18.90 | 2025 | Rexulti |
| Currax Pharmaceuticals LLC | $18.75 | 2023 | Contrave |
| Exact Sciences Corporation | $16.90 | 2025 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tactile Systems Technology INC | $16.38 | 2025 | Nimbl, Flexitouch Plus |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gunjan Raina listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.